Contract Win

IXICO plc

10 December 2024

 

IXICO PLC

("IXICO" or the "Company")

US Client Clinical Trial Contract Win

10 December 2024 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a contract with a new US headquartered client to provide imaging services for a Phase 2 Huntington's Disease clinical trial. The contract value, to be delivered over approximately 2.5 years, is worth over £0.5 million to IXICO.

Huntington's Disease is a rare, hereditary neurodegenerative disorder that leads to the progressive breakdown of nerve cells in the brain, affecting motor skills, cognitive function, mood, and emotional well-being.

The contract award reinforces IXICO's sustained positive commercial momentum, as highlighted in the Company's FY24 Final Results, and aligns with its strategic pillars of 'Innovate, Lead, Scale' to drive expansion and growth. Throughout 2024, IXICO has also secured additional clinical trial contracts across key therapeutic areas, including Huntington's Disease, Parkinsonian Disorders, and Alzheimer's Disease.

Bram Goorden, CEO of IXICO, commented: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease. This contract further demonstrates IXICO's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors. Through this work we are proud to continue our support of the Huntington's Disease community, in collaboration with our sponsor, working towards a breakthrough in this challenging field."

Ends

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Further information:

IXICO plc		[phone]
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)		[phone]
Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales)

About IXICO www.IXICO.com

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

END